Related Experiment Video

Updated: Sep 17, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Bio-engineered microRNA-7 effectively interferes with the Akt3/p53 axis to suppress human non-small cell lung cancer

Qian Huang1, Xiaohua Chu1, Chaofei Yang2

  • 1Lab for Bone Metabolism, Xi'an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi'an, 710072, Shaanxi, China.

Cancer Cell International
|July 3, 2025
PubMed

Insights

Bio-engineered microRNA-7 (miR-7) effectively suppresses non-small cell lung cancer (NSCLC) growth and metastasis. This novel therapy targets Akt3, interacting with the p53 pathway to inhibit tumor development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality with limited effective treatments.
  • The p53 tumor suppressor protein plays a crucial role in NSCLC, and microRNAs (miRs) can modulate its function.
  • Identifying novel therapeutic targets and strategies for NSCLC is critical.

Purpose of the Study:

  • To investigate the role of differentially expressed microRNAs (miRs) in NSCLC, focusing on miR-7.
  • To develop and evaluate bio-engineered miR-7 for its therapeutic potential against NSCLC.
  • To elucidate the mechanism of action of miR-7 in NSCLC, including its interaction with p53 and novel targets.

Main Methods:

  • Bioinformatic analysis to screen for p53-associated miRs differentially expressed in NSCLC.
  • Development of a novel hybrid tRNA scaffold for bio-engineered miR-7 production.
  • In vitro assays to assess the effects of miR-7 on NSCLC cell proliferation, migration, invasion, and apoptosis.
  • In vivo studies using an orthotopic NSCLC xenograft mouse model to evaluate tumor growth inhibition.
  • Identification of novel miR-7 targets and investigation of its interaction with the p53 pathway.

Main Results:

  • Overexpression of miR-7 significantly inhibited NSCLC cell proliferation, migration, and invasion, while inducing apoptosis.
  • Bio-engineered miR-7 demonstrated dramatic inhibition of tumor growth in an in vivo NSCLC mouse model.
  • Akt3 was identified as a novel direct target of miR-7.
  • miR-7 suppressed tumor growth and sensitized NSCLC cells to chemotherapy by repressing Akt, which in turn reduced MDM2-mediated p53 degradation.

Conclusions:

  • miR-7, particularly in its bio-engineered form, exhibits significant anti-tumor activity against NSCLC.
  • miR-7 targets Akt3 and interacts with the p53 pathway to suppress NSCLC development.
  • Bio-engineered miR-7 holds therapeutic potential for treating non-small cell lung cancer.
Keywords:
Akt3Bio-engineered RNACarcinoma, non-small-cell lungmiR-7p53

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.5K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K